In vitro synergistic anti-prion effect of cholesterol ester modulators in combination with chlorpromazine and quinacrine
Introduction
Prions are unconventional infectious agents involved in a number of fatal neurodegenerative diseases of mammals whose replication implies conversion of cellular prion protein isoforms, named PrP C , into diseasespecific isoforms, designated PrP
Sc [1] . Although no treatment is currently available, several compounds have been identified in prion-cell systems as inhibitors of the scrapie-like PK-resistant prion protein (PrP res ), some of which have shown a protective effect in rodent prion models. In no case, however, have inhibitors showed ability to hamper disease progression when treatment was given to animals at the time of symptoms development [2] [3] . In humans, single intraventricular pentosan polysulphate (PPS) treatment was reported to increase the mean survival of seven prion-diseased individuals [4] ; yet, due to the lack of formal drug evaluation in controlled randomized studies, it is not possible to draw any conclusion on the real effectiveness of PPS or that of several other agents tested [5, 6] . The results of a patient-preference quinacrine trial in the UK (PRION-1; ISRCTN 06722585) in patients with Creutzfeldt-Jacob disease (CJD; sporadic, iatrogenic, variant, inherited) were recently published and indicated that a tolerated dose (i.e. 300 mg/day) of quinacrine did not significantly affect the clinical course of disease [7] . This study, however, initially intended to be a partially randomised patient-preference treatment trial, resulted in an observational study and thus, was fraught with confounding factors [7, 8] . More conclusive information on quinacrine effectiveness should be available at the end of a randomised, double-blinded, placebo-controlled study in sporadic CJD (NCT 00183092) started this year in the USA [9] .
Besides the limits of therapies given to individuals with established disease, the clinical relevance of available drugs might be hindered by monotherapybased approaches. From the experience accumulated from other complex diseases, such as cancer and AIDS, one can in fact speculate that any identified pharmacological intervention able to effectively combat the chronic progression of brain damage during prion disease would imply polychemotherapy. Actually, based on this concept, Kocisko et al. found in mice enhanced anti-scrapie effect by using combinations of PPS and porphyrin FeTSP [10] . Thus, efforts should be made to identify more successful therapeutic approaches, as well as novel molecular targets of prion generation. In this context, our studies on the role of cholesterol in cell susceptibility to prion infection/replication showed that brains and ex vivo dermal fibroblasts and peripheral blood mononuclear cells (PBMCs) from sheep genetically susceptible-to or suffering-from scrapie, displayed higher cholesterol ester (CE) levels than sheep carrying a scrapie-resistant genotype, and altered expression levels of the acyl-coenzymeA:cholesterolacyltransferase (ACAT-1; up-regulated) and caveolin-1 (Cav-1; down-regulated) involved in cholesterol esterification and trafficking, respectively [11] [12] [13] . In addition, in persistently prion-infected N2a cells, we found that drugs able to reduce the CE pool, i.e. everolimus, pioglitazone, Sandoz 58035, progesterone, and verapamil, were also able to inhibit PrP res formation [14] . We now report on the anti-prion effect of everolimus, pioglitazone, progesterone, and verapamil in dual-drug combinations with selected prion inhibitors. Quinacrine and chlorpromazine were used as anti-prion agents known to prevent PrP res formation in the endocytic compartment [15] , whereas dextran sulphate 500,000 (DX500) and tannic acid (TA) were used as inhibitors acting on PrP res formation at the plasma membrane site. Like PPS, DX500 is a sulphated polyanion which is thought to bind to PrP C or PrP res [16, 17] , whereas polyphenol tannic acid is known to stabilize plasmamembrane saturated phosphatidylcholine residues, thereby affecting PrP C to PrP res conversion [18] . Our data indicate that, compared to uninfected N2a cells, the prion-infected cultures display general alteration of lipid homeostasis, which can be reverted by treatments with CE modulators combined with the cholesterol-interfering anti-prion drugs chlorpromazine and quinacrine.
Experimental Procedures

Chemicals
Dextran sulphate sodium salt (MW 500 000), verapamil hydrochloride (98%), chlorpromazine hydrochloride, quinacrine dihydrochloride, and progesterone, were purchased from Sigma-Aldrich (Italy). Tannic acid was purchased from MP Biomedicals (USA). Everolimus was provided by Novartis (Switzerland), and pioglitazone by Takeda (Japan). Dextran sulphate 500 was solubilised in OptiMEM, and stored at -20°C. Everolimus was solubilised in 100% ethanol and stored at +4°C. Pioglitazone was solubilised in 100% ethanol and stored at room temperature. Stock solutions of the other compounds were prepared in DMSO and stored at -20°C.
Cell lines and PrP analysis
Mouse neuroblastoma N2a cell line and sublines persistently infected with the 22L and RML strains of mouse-adapted scrapie (22L-N2a, RML-N2a), were a generous gift by Byron Caughey, NIH/NIAID Rocky Mountain Laboratories, USA. Cells were grown at 37°C, 5% CO 2, in OptiMEM supplemented with 10% FBS (Gibco, Invitrogen; Italy), 2mM L-glutamine, 50 U/ml penicillin G sodium and 50 µg/ml streptomycin sulphate (Gibco, Invitrogen; Italy), and split every 3 to 4 days. Cell lines were stored in liquid nitrogen and working cultures were replaced every two-three months. All experiments were carried out in exponentially growing cells or subconfluent cultures. PrP C and PK-resistant PrP (PrP res ) were detected in cell lysates by dot blot procedure with the mouse anti-PrP antibody 6H4 (Prionics, Zurich; 1:5.000) as previously described [14] . 
Effect of single
Evaluation of drug efflux activity
Drug efflux activity of P-gp protein was determined by measuring intracellular accumulation of radioactive vinblastine as previously described [20] . In brief, 22L-N2a cells were seeded at 1x10 4 cells/ml in growth medium (OptiMEM supplemented with 10% FCS, 100 units/ml penicillin, 100 µg/ml streptomycin) in a Microtest flatbottom 24-well plate with a low-evaporation lid (Becton Dickinson, USA). Cultures were allowed to settle overnight and then further incubated in the absence and in the presence of different concentrations of the cholesterol inhibitors. After 96 hours of incubation, cell cultures were washed twice with PBS and re-incubated at 37°C in ½ final volume of fresh growth medium with or without the drugs. One hour later, cells were re-fed with equal volume of identical pre-warmed medium supplemented with 0.1 µCi/ml [G-
Staining of intracellular lipids
To visualize intracellular lipids, N2a and 22L-N2a cells were seeded at 1x10 4 /ml in growth medium in Microtest flat-bottom 24-well plates (Becton Dickinson, USA). After overnight settlement, 22L-N2a cultures were drugtreated under conditions used for evaluation of anti-PrP res activity. Each drug and drug combination was tested in triplicate. After 96-hour incubation, untreated and drug treated cultures were washed with PBS, fixed by soaking in 10% formalin and then stained with Oil red-O (ORO) (Sigma), Nile red (9-diethylamino-5H-benzo[α] phenoxazine-5-one, Fluka, Buchs, SG, Switzerland) and filipin (Sigma). ORO is a lipid-soluble dye which stains NL (i.e. CE and triglycerides, TG), but not free cholesterol (FC). ORO staining was performed in 60% isopropyl alcohol, followed by Mayer's hematoxylin counterstaining for nuclei [14] . After staining, cells were imaged using a Leitz inverted-phase microscope fitted with a digital camera. Neutral lipids (NL) appear as bright red spots in the cell cytoplasm. At least two different fields per sample were imaged and analyzed. Red ORO intensity was quantified by NIH Image J software utilizing four different selected regions of interest (ROIs), and values expressed as integrals of the intensity given as 'arbitrary units' (pixels/cm2) ± SE of triplicate wells.
Nile red is a fluorescent dye that stains differentially polar lipids (i.e. phospholipids, PL) and NL (i.e. CE and TG) [21] . PL show a prevalent red emission, while NL show both red and green emission. Red emission was observed with 540±12.5 excitation and 590 LP emission filters. Green emission was observed with 460±25 excitation and 535±20 emission filters. Filipin is a fluorescent dye which stains only free cholesterol (FC; blue emission). Filipin was observed with 360±20 excitation and 460±25 emission filters. Filipin and Nile red emissions were completely separated by the above indicated filters, so the two fluorochromes could be used in combination on the same cells [22] . Quantitative image analysis was performed with the ImagePro Plus package (Media Cybernetics, Silver Springs, MD).
Cellular lipid content, synthesis, and efflux
For determinations of the different lipid subclasses in N2a and 22L-N2a cells, total lipids (TL) were extracted with cold acetone from a total of 30x10 6 of each cell line collected from sub-confluent flasks. Extracted lipids were split into two equal aliquots and air dried: one aliquot was used to determine total cholesterol (TC) by the cholesterol oxidase method (Sclavo Diagnostics, Siena, Italy); the other aliquot, after drying, was resuspended in 100 µl of chloroform and analysed for lipid subclasses by thin layer chromatography (TLC) on kiesegel plates using a solvent system containing n-heptane/isopropyl ether/formic acid (60:40:2 v/v/v). Separated bands were identified as FC, CE, and TG by comparison with reference standards run simultaneously side-by-side and visualized under iodine vapors. Bands were excised and their masses determined by the cholesterol oxidase (for FC and CE) and peroxidase (for TG) assay methods (Sclavo Diagnostics, Siena, Italy).
To determine the effect of drugs and drug combinations on lipid synthesis and efflux, N2a and 22L-N2a cells were seeded at 1x10 4 /ml in growth medium in Microtest flat-bottom 24-well plates (Becton Dickinson, USA). After overnight settlement, 22L-N2a cultures were drug-treated and incubated under the condition used for evaluation of anti-PrP res activity. Each drug and drug combination was tested in triplicate. Six hours before harvesting, 5 μCi/ml sodium 14 C-acetate (DuPont, NEN; specific radioactivity 50 mCi/mmol) were added to each well. At the end of labelling, TL in the cell monolayers and in the growth media were extracted with cold acetone and lipid subclasses separated by TLC as described above. The incorporation of 14 C-acetate into lipid sub fractions was measured in a Liquid Scintillation Counter. Efflux of 14 C-TL was expressed as the percentage of the radioactivity recovered in medium/total radioactivity (cells + medium).
Statistical analysis
Unless otherwise indicated, data are reported as mean ± standard error (SE). Statistical calculations were performed using the statistical analysis software Origin 8.0 version (Microcal, Inc, Northampton, MA, USA). Data analysis was done using the Student t-test. A value of P<0.05 was considered statistically significant.
Results
Anti-PrP res activity of prion inhibitors in combination with CE modulators
The inhibitory effect of single vs. dual-drug treatments on PrP res generation was evaluated in 22L-infected cells by dot blot procedure [23] , a method equally reliable but more suitable than Western blot-based assay for comparative studies of multiple drugs. 22L-N2a cell cultures were exposed to fractions of the EC 50 (serial ½ drug dilutions) of each compound, alone and in association. Dual-drug treatments were either performed at the same time or in sequential order: 8 hrs treatment with one drug before adding the second drug. Type and degree of drug interactions were analyzed by both isobole and FIC index methods [19] . The effect of combined treatments ranged from synergism to indifference, depending on the prion inhibitor considered, drug concentration, and the temporal sequence of drug addition. Simultaneous treatments, as well as sequential combination with prion inhibitors that preceded CE modulators, always resulted in an additive or indifferent type of interaction (not shown). Sequential combinations comprising any CE modulator followed by dextran sulphate or tannic acid also resulted in an additive or indifferent type of interaction. Isoboles and FIC indices of combinations comprising everolimus and progesterone followed by dextran sulphate and tannic acid are shown in Figure 1A . By contrast, a marked enhancement of the anti-prion effect was obtained when cells were treated with any CE modulator followed by chlorpromazine. Pretreatments with everolimus, pioglitazone, progesterone, or verapamil, resulted in anti-prion effects in the range of synergism, as indicated by either FIC values (0.21-0.73) or data points in isoboles (Figure 2A ). (Figure 1-3B) . Notably, similar drug interactions against PrP res formation were also obtained in N2a cells infected with the RML prion strain (data not shown). Anti-prion effects were not due to cytotoxicity, as neither single nor dual-drug treatments affected MTT viability at active concentrations (Table 1) .
Effect of CE modulators on P-gp drug efflux activity
In multidrug-resistant cell lines, progesterone and verapamil are chemo-sensitizers of unrelated cytotoxic agents via the inhibition of membrane drug-efflux P-gp protein [24, refs therein] . To investigate whether synergistic anti-prion effects were due to increased cell retention of chlorpromazine and quinacrine induced by P-gp inhibition, the overall drug-efflux potential of 22L-N2a cells was investigated. Cells were exposed to the CE modulators for either 1 hour (i.e. standard procedure for measuring drug-efflux P-gp activity) or 96 hours (i.e. our test condition to evaluate anti-prion activity), and then pulse-labelled with 3 H-vinblastine, a known P-gp substrate [20, 24] . Actually, both verapamil and progesterone, at concentrations close to their EC 50s (i.e. 10 µM and 35 µM, respectively), increased labelled vinblastine content with respect to untreated cultures (Table 2) . Verapamil was a better P-gp inhibitor than progesterone and determined higher vinblastine retention after both short (1 h) and prolonged (96 h) exposure to the drug. However, treatments with concentrations (i.e. 7.5 µM and 2.5 µM, respectively) closer to synergistic ones, had no effect on vinblastine retention. Everolimus showed negligible anti-P-gp activity following treatments with 1 µM and 0.5 µM, and had no effect at a dose (0.05 µM) higher than that showing the strongest antiprion synergism in combination with both chlorpromazine and quinacrine. Intriguingly, a high dose of pioglitazone (40 µM), while not affecting vinblastine influx after short treatment, determined a marked retention of labelled vinblastine after prolonged treatment.
Effect of single vs. dual-drug combinations on intracellular lipids
Given that observed synergism was unlikely due to increased cell retention of chlorpromazine or quinacrine, we investigated whether combined drugs interacted at the level of lipid metabolism. The effect on intracellular lipids of a drug combination with marked anti-PrP res synergism, such as everolimus (EVE, 0.02 µM) and chlorpromazine (CP, 2 µM), was evaluated by staining the cells with dyes with affinity for different lipids (Oil Red O for neutral lipids; Nile red for neutral lipids and phospholipids; Filipin for free cholesterol). As expected [14] , Oil Red O (ORO) staining revealed significantly higher neutral lipids (NL) in the 22L-infected than in the uninfected N2a cells ( Figure 4A and B). However, both single and combined drug treatments markedly reduced red ORO intensity in the 22L-infected cell line. More detailed information was obtained with Nile red, a fluorescent hydrophobic probe that, being based on the different sensitivity of red and green emissions to lowand high-hydrophobic lipids, respectively, allowed us to distinguish neutral from polar lipids. Combined staining with Nile red and Filipin, a fluorescent sterol binding agent, allowed us to also co-localize free cholesterol (FC; blue emission). With respect to uninfected cells, 22L-infected N2a showed an increase in both polar (phospholipids, PL) and NL (i.e. CE and triglycerides, TG), as well as in FC ( Figure 5A and B). In agreement with ORO data, 22L-N2a cells showed a higher green emission signal -indicative of higher NL content. In addition, Nile-red staining in the infected cells appeared as spread greenish fluorescence, rather than being Figure 5C , compare N2a with 22L-N2a). 22L-N2a cells showed a more intense Filipin fluorescence -indicative of a higher FC content, some of which was also dispersed in the cytoplasm. Single treatment of infected cultures with everolimus determined a marked reduction of all forms of intracellular lipids, whereas treatment with chlorpromazine had a lower, although significant, effect on both PL and CE, but no significant effect on FC. Interestingly, combined treatments of infected cells with everolimus and chlorpromazine appeared to generate a lipid profile similar to that of the untreated-uninfected cells.
Lipid content in N2a vs. 22L-N2a by TLC
The above data clearly indicated that 22L-infected cells displayed higher NL compared to uninfected cells. Table 2 . MDR1/P-gp drug efflux activity in 22L-infected N2a cell lines.
Values represent the mean ±SD of triplicate determinations from three independent experiments.
analyse lipids in cell extracts. As seen in Figure 6 (A and B), the cholesterol oxidase assay revealed 1.7-fold higher content of total cholesterol (TC) in the lysates of infected cells. Separation of lipid subclasses by TLC showed higher levels not only of FC (1.6-fold) and CE (5.5-fold), but also of TG (1.9-fold). Thus, lipid analysis by enzymatic and chemical means confirmed, even though not in a stoichiometric manner, that prion infected cells display increased levels of all lipid subfractions, and additionally identified the CE pool as the most altered.
Effect of single vs. dual-drug combinations on lipid synthesis and efflux in 22L-N2a
To draw more consistent conclusions regarding the effects of drugs and drug combinations on cellular lipid homeostasis, we compared neosynthesis of lipids (FC, CE, TG) and lipid efflux (mainly FC) in N2a vs. 22L-infected N2a cells, either untreated or treated with single and dual-drug combinations of everolimus (EVE, 0.02 µM), chlorpromazine (CP, 2 µM), and quinacrine (Q, 0.2 µM). Once again, 14 C-acetate incorporated into total lipids (TL) was higher in the 22L-N2a than in N2a cells ( Figure 7A) . In spite of a slight increase in TL efflux in the 22L-infected cultures, the percentage of TL efflux did not significantly differ between the two cell lines. TLC separation of lipid subclasses showed that the higher lipid syntheses in the 22L-N2a cells was due to increased neosynthesis of FC (1.5-fold), CE (2-fold), and TG (1.6-fold) ( Figure 7B ). Although syntheses of uninfected N2a were also affected by single and combined drug treatments (not shown), in the prion-infected cultures combined drugs seemed to act in concert triggering lipid syntheses back at levels of untreated-uninfected cells ( Figure 7A and B) .
Discussion
In the present study we found that drugs targeting steps of cholesterol metabolism/esterification were able to enhance the anti-prion activity of chlorpromazine and quinacrine by reducing their EC 50s up to 10-fold. Synergistic drug interactions were obtained in sequential combination of chlorpromazine or quinacrine with i) everolimus, an immunosuppressant agent that inhibits cholesterol esterification by an as yet unknown mechanism [25, 26] ; ii) pioglitazone, an anti-diabetic drug that induces cell redistribution of free fatty acids [27] ; iii) verapamil, a calcium-blocking drug that inhibits cholesterol trafficking from the plasma membrane to the endoplasmic reticulum [21, refs therein] ; and iv) progesterone, a sterol hormone that affects cholesterol trafficking from both the plasma membrane and lysosomes [28, 29] . Chlorpromazine and quinacrine are known to inhibit prions in vitro and to some extent also in vivo [2, 30] . Although the exact mechanism(s) remains to be established, these drugs have been involved in i) competitive inhibition of endogenous sulfated glycosaminoglycans (GAGs)-PrP interaction, essential for PrP res formation or stabilization in the endosomes; ii) unfolding of PrP res by drug-induced endosome/ lysosome accumulation of chaperone-like factor(s); iii) destabilization of PrP res by alteration of lysosomal pH [15] . Recent evidence, however, not formally excluding the above mechanisms, indicates that quinacrine and chlorpromazine might exert anti-prion effect by additional mechanisms that involve interference with intracellular cholesterol. Quinacrine has been reported to determine destabilization of cholesterol-rich membrane domains (DRMs or rafts) [31] . Worthy of mention, these Authors also described the anti-prion activity of progesterone and the synergistic anti-prion effect of quinacrine in combination with the cholesterol biosynthesis inhibitor simvastatin. As for chlorpromazine, a study on the role of cellular cholesterol in the pathogenesis of schizophrenia, indicated that drug-induced transcriptional activation of cholesterol biosynthesis could represent a novel mechanism of action for some antipsychotic drugs, chlorpromazine being one of the most potent [32] . Moreover, more recently Vik-Mo et al. [33] showed that antipsychotic and antidepressant drugs also induce transcriptional activation of genes involved in cholesterol transport and efflux. Hence, the observed anti-prion synergistic effects may arise from pharmacologicinduced cholesterol homeostasis. Compared to parental uninfected N2a cells, in fact, prion-infected cultures displayed a general derangement of type and distribution of most intracellular lipids, including free cholesterol, cholesterol esters, phospholipids, and triglycerides.
These results confirm and extend our previous findings in the same cell model [14] and in the ovine scrapie [11] [12] [13] , and further support the presence of a tight association between prion infection/susceptibility and altered cholesterol homeostasis. In agreement with our results, altered cholesterol metabolism/esterification with over-expression of ACAT-1 (soat1) was reported in mice brains during the course of experimental scrapie [34, refs therein] , and up-regulation of cholesterol biosynthesis was recently described following prion A total of 30x10 6 of each cell culture was collected from sub-confluent flasks. Extracted lipids were split into two equal aliquots and air dried: one aliquot was used to determine total cholesterol (TC) by the cholesterol oxidase method; the other aliquot was resuspended in 100 µl of chloroform and analysed for lipid subclasses by TLC (see section 2. 
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infection in various types of neuronal cells, N2a included [35] . Interestingly, Bach et al. [35] presented evidence that modification of cholesterol biosynthesis appears a characteristic response of neurons and neuronal cell lines to prion challenge, and suggested that prions themselves may have the potential to alter cell cholesterol homeostasis in a cell-type specific manner.
Although at present we have no mechanistic explanation for the association found in sheep between cholesterol alteration and scrapie-susceptible prion genotype [11] [12] [13] , we can speculate that prions may as well have the potential to alter cholesterol homeostasis in a genotypetype specific manner. Whatever mechanism is involved, the emerging picture is that of a direct relationship between prion infection/replication and lipid homeostasis alterations. These modifications, likely translating into changes in the raft-membrane integrity, may in turn support the aberrant processing of prion protein [36] . The ability of combined treatments of everolimus and chloropromazine, or everolimus and quinacrine, to trigger lipid homeostasis in the prion-infected cells, supports this hypothesis and may account for the enhanced antiprion effect of these drug combinations. On the other hand, a mechanism involving inhibition of the drug-efflux pump P-gp seems unlikely. Firstly, most synergistic effects against PrP res were obtained with P-gp inhibitors (progesterone and verapamil) at concentrations 4/5-fold lower than those required to increase vinblastine influx. Secondly, everolimus, at the highest concentration tested (i.e. 1 µM) increased vinblastine retention by only 10%. Worthy of note, a recent study by Bate et al. reported a higher toxicity of some ACAT inhibitors (i.e. TMP-153, FR179254 and YIC-C8-434) in prion-infected ScGT1 and ScN2a cell lines vs. uninfected cells [37] . However, none of the cholesterol ester modulators used in the present study affected viability of 22L-infected and uninfected N2a cells, neither in single nor in combinatory experiments.
Taken together these results indicate that inhibition of prion generation can be readily potentiated by combinatorial drug treatments, and that steps of cholesterol/cholesterol esterification metabolism may represent suitable targets. While these findings are suggestive, the potential effectiveness of these drugs and drug-combinations yet remains to be confirmed in other prion models as well as in cell conditions that may better reflect the in vivo prion biology. In this respect, an interesting study in prion-infected N2a cells showed that cell division strongly influences the accumulation of PrP res and suggested that, since the process of cell division may intensify the kinetics of PrP Sc clearance, inhibitory activity in neuronal cell lines may not reflect real effectiveness in the neurons [38] . Moreover, our previous studies on the role of cholesterol metabolism during cell proliferation indicated an association between the cell capability to synthesize and retain cholesterol esters and the cell growth rate potential [20, 24, 25] . Therefore, given that inhibitory activity of anti-prion compounds in culture seems to be influenced by the growth phases of target cells, and given that cell cycle progression appears itself associated with changes of cholesterol homeostatic mechanisms, the evaluation of these drugs and drug combinations in non-dividing stationary cultures may provide further insight on the mechanism(s) linking cholesterol metabolism to the processing of prion protein.
